Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJan 08, 2026
DataAggregated Company Financials
Companies178
  • 7D2.5%
  • 3M2.6%
  • 1Y-3.1%
  • YTD2.7%

The Pharma industry is up 2.5% in the last week, with Sun Pharmaceutical Industries up 3.7%. However, the industry is down 4.8% over the past year. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 08 Jan 2026₹20.9t₹4.2t₹613.3b29x34.1x4.9x
Sat, 06 Dec 2025₹20.6t₹4.2t₹612.9b29x33.6x4.9x
Mon, 03 Nov 2025₹20.2t₹4.1t₹594.9b29.9x33.9x4.9x
Wed, 01 Oct 2025₹19.8t₹4.1t₹588.1b29.9x33.6x4.9x
Fri, 29 Aug 2025₹20.0t₹4.1t₹589.1b29.4x33.9x4.9x
Sun, 27 Jul 2025₹20.9t₹4.0t₹596.9b32.8x35x5.2x
Tue, 24 Jun 2025₹19.9t₹4.0t₹595.3b31.5x33.4x5x
Thu, 22 May 2025₹19.9t₹4.0t₹582.9b32.1x34.1x5x
Sat, 19 Apr 2025₹19.5t₹3.9t₹559.2b28.5x34.8x5x
Mon, 17 Mar 2025₹18.5t₹3.9t₹559.4b27x33.2x4.8x
Wed, 12 Feb 2025₹19.3t₹3.9t₹548.1b30.4x35.2x5x
Fri, 10 Jan 2025₹21.0t₹3.8t₹527.0b33.9x39.8x5.5x
Sun, 08 Dec 2024₹20.8t₹3.8t₹526.7b36x39.5x5.5x
Tue, 05 Nov 2024₹21.1t₹3.8t₹504.9b37.6x41.7x5.6x
Thu, 03 Oct 2024₹21.6t₹3.7t₹492.6b41.6x43.8x5.8x
Sat, 31 Aug 2024₹21.2t₹3.7t₹492.4b39.8x43x5.7x
Mon, 29 Jul 2024₹19.5t₹3.7t₹459.9b36.7x42.4x5.3x
Wed, 26 Jun 2024₹17.4t₹3.6t₹448.3b33.2x38.9x4.9x
Fri, 24 May 2024₹17.2t₹3.5t₹453.6b34x37.9x4.8x
Sun, 21 Apr 2024₹16.6t₹3.5t₹418.9b33.2x39.6x4.8x
Tue, 19 Mar 2024₹16.7t₹3.5t₹418.7b32.1x39.9x4.8x
Thu, 15 Feb 2024₹16.7t₹3.5t₹425.0b33.9x39.2x4.8x
Sat, 13 Jan 2024₹15.7t₹3.4t₹395.3b35.2x39.6x4.6x
Mon, 11 Dec 2023₹14.3t₹3.4t₹395.1b31.4x36.1x4.2x
Wed, 08 Nov 2023₹13.4t₹3.3t₹378.4b30.1x35.4x4x
Fri, 06 Oct 2023₹13.3t₹3.3t₹369.5b30x35.9x4.1x
Sun, 03 Sep 2023₹12.8t₹3.3t₹367.0b29.3x34.9x3.9x
Tue, 01 Aug 2023₹12.8t₹3.2t₹345.7b28.2x36.9x4x
Thu, 29 Jun 2023₹11.5t₹3.2t₹342.4b26.6x33.6x3.6x
Sat, 27 May 2023₹10.6t₹3.1t₹295.4b27.4x35.7x3.4x
Mon, 24 Apr 2023₹9.9t₹3.0t₹277.7b26.4x35.8x3.3x
Wed, 22 Mar 2023₹9.3t₹3.0t₹277.5b23.6x33.6x3.1x
Fri, 17 Feb 2023₹9.7t₹3.0t₹277.3b23.4x35.1x3.3x
Sun, 15 Jan 2023₹9.9t₹2.9t₹275.2b26x36.2x3.4x
Price to Earnings Ratio

36.2x


Total Market Cap: ₹9.9tTotal Earnings: ₹275.2bTotal Revenue: ₹2.9tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.7x.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 31% per year over the last three years.
  • Revenues for these companies have grown 13% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market0.84%
Healthcare2.37%
Pharma2.46%
Pharma2.46%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.78k3.7%
+₹150.9b		-3.0%PE40.9x
500420 Torrent Pharmaceuticals₹4.09k6.5%
+₹84.5b		23.0%PE64.7x
MANKIND Mankind Pharma₹2.31k5.2%
+₹47.6b		-19.7%PE54.6x
500257 Lupin₹2.21k4.8%
+₹46.4b		-1.7%PE23.4x
ALKEM Alkem Laboratories₹5.81k5.4%
+₹35.9b		4.4%PE29.4x

Latest News

SUNPHARMA
₹1,782.60
Sun Pharmaceutical Industries
7D
3.7%
1Y
-3.0%
COHANCE
₹503.25
Cohance Lifesciences
7D
-4.8%
1Y
-54.2%

COHANCE: Leadership Change And US Funding Will Support 2030 Revenue Ambition

Analysts have trimmed their price target on Cohance Lifesciences to ₹801.11 per share, citing updated assumptions for long term revenue growth, profit margins and future P/E multiples that leave their fair value view essentially unchanged. What's in the News Board meeting scheduled on February 12, 2026, to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025 (company filing).
500124
₹1,242.60
Dr. Reddy's Laboratories
7D
-2.2%
1Y
-9.3%

500124: Biosimilar Approvals Will Support Future Upside As Regulatory Issues Remain Contained

Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,615, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions that they view as offsetting each other. What's in the News Dr. Reddy's received five separate orders from the GST Authority for tax demand, interest, and penalties related to alleged excess input tax credit for FY2018-19 to FY2022-23, with penalties of ₹1,89,30,110, ₹80,41,186, ₹3,52,95,063, ₹1,45,04,023 and ₹70,86,675 respectively.
ALKEM
₹5,806.50
Alkem Laboratories
7D
5.4%
1Y
4.4%

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Jan 02
Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?
524632
₹52.23
Shukra Pharmaceuticals
7D
-11.8%
1Y
194.5%
PFIZER
₹4,928.30
Pfizer
7D
-1.2%
1Y
-8.4%

Pfizer Limited's (NSE:PFIZER) Price Is Out Of Tune With Earnings

Dec 30
Pfizer Limited's (NSE:PFIZER) Price Is Out Of Tune With Earnings
CIPLA
₹1,467.90
Cipla
7D
-2.9%
1Y
-1.8%

We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt

Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
AUROPHARMA
₹1,235.40
Aurobindo Pharma
7D
4.4%
1Y
-3.6%

AUROPHARMA: Margin Optimism Will Face Pressure From Execution And Regulatory Risks

The analyst price target for Aurobindo Pharma has been raised from ₹863 to ₹939 as analysts update their models to reflect modestly higher margin expectations and a slightly richer future earnings multiple despite a marginal trim to long term revenue growth assumptions. Analyst Commentary While the recent price target revision for Aurobindo Pharma reflects greater confidence in margins and earnings quality, not all signals across the broader research landscape are uniformly positive for comparable growth and innovation driven names.
500420
₹4,091.25
Torrent Pharmaceuticals
7D
6.5%
1Y
23.0%

500420: Patent Settlement And Stable Outlook Will Shape Future Risk Profile

Narrative Update on Torrent Pharmaceuticals Analysts have maintained their price target on Torrent Pharmaceuticals at ₹4,024. This reflects unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples that continue to support the current fair value assessment.
IPCALAB
₹1,514.20
Ipca Laboratories
7D
6.7%
1Y
-10.6%

IPCALAB: Improved Margins And Lower Multiple Will Support Future Upside Potential

Analysts have trimmed their price target on Ipca Laboratories by approximately ₹80 to around ₹1,730, reflecting slightly softer revenue growth assumptions, while still factoring in improved profit margins and a lower future P/E multiple. What's in the News Board meeting scheduled on October 17, 2025, at 17:00 IST to discuss corporate matters and ongoing strategic priorities (company filing).
500257
₹2,213.55
Lupin
7D
4.8%
1Y
-1.7%

500257: Biosimilar And US Regulatory Progress Will Support Balanced Share Performance

Analysts have modestly maintained their conviction on Lupin with the analyst price target effectively unchanged at ₹2,280.84, reflecting stable assumptions on revenue growth, profitability and valuation multiples despite minor model refinements. What's in the News European regulator CHMP issued a positive opinion for Lupin's biosimilar ranibizumab Ranluspec for multiple retinal indications, moving the product closer to centralized EU approval and commercialization via Sandoz and Biogaran in select markets (CHMP, EMA).
MANKIND
₹2,311.80
Mankind Pharma
7D
5.2%
1Y
-19.7%

MANKIND: Strong Profitability Outlook Will Support Future Bullish Re-Rating

Narrative Update Analysts have modestly trimmed their fair value estimate for Mankind Pharma to ₹3,260 from ₹3,300, reflecting slightly lower expected revenue growth and valuation multiples, partly offset by an improved profit margin outlook. What's in the News Board meeting scheduled for November 6, 2025, to review and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments) Valuation Changes Fair Value Estimate reduced slightly to ₹3,260 from ₹3,300, reflecting a modest downward revision in intrinsic value.
EMCURE
₹1,527.20
Emcure Pharmaceuticals
7D
11.9%
1Y
5.6%
500488
₹28,493.75
Abbott India
7D
-2.0%
1Y
-3.7%
APLLTD
₹823.70
Alembic Pharmaceuticals
7D
-2.7%
1Y
-22.7%

Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price

Nov 12
Why We're Not Concerned About Alembic Pharmaceuticals Limited's (NSE:APLLTD) Share Price
506820
₹8,464.70
AstraZeneca Pharma India
7D
-6.1%
1Y
22.8%